New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Compounded tirzepatide is available in non-injection formats ... Section 5 – User Journey and Market Tone Public discussions around GLP-1 weight management increasingly focus on the patient journey - ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

Tirzepatide: A dual-acting medication that combines GLP-1 and GIP ... Tirzepatide is newer to the market and may be less widely available or more expensive than semaglutide.

Eli Lilly is cutting the price of its popular weight-loss drug to compete with counterfeit versions. Zepbound will be sold for $399 to $549 a month, compared to a previous list price of $1,059.

Eli Lilly's weight-loss drug Zepbound (tirzepatide) is facing a shortage in the U.S. due to increased demand, according to the FDA.

Eli Lilly's CEO thinks tirzepatide, an experimental diabetes treatment, could also treat obesity. In a clinical trial, people with diabetes who received tirzepatide lost on average 25 pounds.

Summary. This week Lilly surpassed Johnson & Johnson to become the world's largest Pharma by market cap. That is quite astonishing given JNJ drove $95bn of revenues last year, compared to Lilly's ...